AstraZeneca's stomach cancer drug extends overall survival, late-stage trial data finds
AstraZeneca's stomach cancer drug extends overall survival, late-stage trial data finds Reuters
Covered in this story
Call it yourself
No calls on $AZN.L yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on AstraZeneca →Summary aggregated from Reuters's public RSS feed. The full reporting belongs to Reuters — please read it on their site.